Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical
Cytomegalovirus reactivation · people with chronic lymphocytic leukaemia
Anti‐leukaemic therapy plus alemtuzumab leads to higher cytomegalovirus reactivation compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (high certainty).
1 finding from 1 review
- RR 10.52 [1.42, 77.68]2 studies · 350 participantsHigh